Navigation Links
In surprise finding, blood clots absorb bacterial toxin
Date:12/9/2013

Blood clots play an unexpected role in protecting the body from the deadly effects of bacteria by absorbing bacterial toxins, researchers at the University of California, Davis, have found. The research was published Dec. 2 in the journal PLOS ONE.

"It's a significant addition to the short list of defenses that animals use to protect themselves against toxin-induced sepsis," said Peter Armstrong, professor of molecular and cellular biology at UC Davis and senior author on the paper.

Even with modern antibiotics, septic shock from bacterial infections afflicts about 300,000 people a year in the U.S., with a mortality rate of 30 to 50 percent. Septic shock is caused by Gram-negative bacteria, which release a toxin called lipopolysaccharide or endotoxin. In small amounts, lipopolysaccharide triggers inflammation. When infections with these bacteria get out of hand, lipopolysaccharide courses through the bloodstream, causing catastrophic damage to organs and tissues.

These toxins cause disease in a variety of animal species lipopolysaccharide is also toxic to both horseshoe crabs and lobsters, separated from humans by hundreds of millions of years of evolution. In humans and other mammals, blood clots quickly form from a mix of specialized blood cells and protein fibers. Arthropods like horseshoe crabs and lobsters can also form clots in response to injury, with a different mix of cells and proteins.

Clots protect and help to seal wounds, prevent blood or body fluids from leaking out and form a physical barrier that entangles and blocks bacteria from entering the body. The new study shows that they also actively soak up lipopolysaccharide, reducing its release from the wound site into the body, where it could cause disease or even death.

Armstrong's laboratory had previously developed fluorescent labels to show that a lipopolysaccharide-like molecule is present in chloroplasts, structures inside cells of green plants that carry out photosynthesis and are thought to be descended from bacteria. As he also studies the role of blood clots in resisting infections, Armstrong decided to test the same techniques on blood clots that had been exposed to bacteria or to bacterial lipopolysaccharide. The fluorescent probes lit up the clots, showing that the clot fibers bound lipopolysaccharide to their surfaces.

"I was ecstatic," Armstrong said. "It was one of those moments that makes the rest of the slogging worthwhile."

Armstrong and colleagues Margaret Armstrong at UC Davis and Frederick Rickles at George Washington University looked at clots of blood, or its equivalent, from humans, mice, lobsters and horseshoe crabs. In all four species, they found that fluorescently tagged lipopolysaccharide was bound to the fibers of the blood clot. The toxin was too tightly attached to be readily removed by chemical treatments that remove weakly bound macromolecules from proteins.

During a sabbatical leave in the laboratory of Dr. Bruce Furie at Beth Deaconess Medical Center and Harvard University, Armstrong was also able to film clots in blood vessels of live mice and showed that these in vivo clots took up lipopolysaccharide in real time. These in vivo experiments, he said, confirm the bench-top observations and offer new insights into the pathology of sepsis.

One of the deadly consequences of septic shock is disseminated intravascular coagulation, when blood clots form rapidly throughout the body. But the new results suggest that on a small and local scale, this might be part of a protective mechanism against sepsis these intravascular clots can soak up quantities of lipopolysaccharide from the blood. They also show that rather than being a simple physical barrier, blood clots play an active and dynamic role in protecting the body from infections.

Parts of the research were carried out at the Woods Hole Marine Biological Laboratory. The work was funded by a grant from the National Science Foundation.


'/>"/>

Contact: Andy Fell
ahfell@ucdavis.edu
530-752-4533
University of California - Davis
Source:Eurekalert

Related biology news :

1. Stanford researchers surprised to find how neural circuits identify information needed for decisions
2. Surprises discovered in decoded kiwifruit genome
3. Family tree of fish yields surprises
4. Surprise finding reveals how adaptive our immune systems can be
5. Surprise species at risk from climate change
6. Science surprise: Toxic protein made in unusual way may explain brain disorder
7. Peru surprises with 2 new amazing species of woodlizards
8. EARTH: Antarctic trees surprise scientists
9. Diet of early human relative Australopithecus shows surprises, says Texas A&M researcher
10. An evolutionary surprise
11. New method for stabilizing hemoglobin could lead to stable vaccines, artificial blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today ... for the sale of 12,835,490 shares of its common ...  ecosystem of companies. In connection with the sale of its ... in cash and issue to GlobeImmune 200,000 shares, an ... "We are pleased to enter into ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
Breaking Biology Technology: